Furthermore, the percentage of CD45− tumor cells expressing PD-L1 was not significantly altered between RT-treated and RT+L19–IL2-treated tumors and almost undetectable upon anti-PD-L1 treatment due to the therapeutic anti-PD-L1 antibody blocking the binding of the fluorescent detection antibody. This evidence concerns the gene CD274 and neoplasm.